In the videos below, Dr. Peter Anderson talks about ONC201 and his Phase II – Neuroendocrine Tumors (NCT03034200) at The Cleveland Clinic. The clinical trial is evaluating ONC201 in patients with neuroendocrine tumors. These tumors are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Dr. Peter Anderson is the Principal Investigator for the trial.
Content Warning: These Videos Are Intended for Doctors and Health Care Professionals.
The interview is divided into six video sections, each of which is between 1:30 minutes and 3:30 minutes long: